eMedicine Specialties > Cardiology > Arrhythmias

Torsade de Pointes

Author: Jatin Dave, MD, MPH, Instructor, Department of Medicine, Department of Internal Medicine, Division of Aging, Harvard Medical School; Staff Physician, Brigham and Women's Hospital
Coauthor(s): Revat Lakhia, MD, Visiting Staff, Department of Internal Medicine, Brigham and Women's Hospital; Graduate Student in Public Health, Department of Health Science, West Chester University of Pennsylvania
Contributor Information and Disclosures

Updated: Jul 30, 2009

Introduction

Background

Torsade de pointes, literally meaning twisting of points, is a distinctive form of polymorphic ventricular tachycardia (VT) characterized by a gradual change in the amplitude and twisting of the QRS complexes around the isoelectric line. Torsade de pointes (torsade) is associated with a prolonged QT interval, which may be congenital or acquired. Torsade (not long QT) usually terminates spontaneously but frequently recurs and may degenerate into ventricular fibrillation.

Torsade de pointes. Asymptomatic patient on eryth...

Torsade de pointes. Asymptomatic patient on erythromycin had marked QT prolongation on ECG findings. Patient was profoundly hypomagnesemic and hypokalemic. This shows an example of recurrent nonsustained torsade de pointes that occurred several hours after the ECG was performed. With discontinuation of the erythromycin and aggressive repletion of the magnesium and potassium, no further torsade de pointes occurred and the patient's QT interval returned to normal.

Torsade de pointes. Asymptomatic patient on eryth...

Torsade de pointes. Asymptomatic patient on erythromycin had marked QT prolongation on ECG findings. Patient was profoundly hypomagnesemic and hypokalemic. This shows an example of recurrent nonsustained torsade de pointes that occurred several hours after the ECG was performed. With discontinuation of the erythromycin and aggressive repletion of the magnesium and potassium, no further torsade de pointes occurred and the patient's QT interval returned to normal.

Pathophysiology

The association between torsade and a prolonged QT interval has long been known, but the mechanisms involved at the cellular and ionic levels have been made clearer in approximately the last decade.1 The abnormality underlying both acquired and congenital long QT syndromes is in the ionic current flow during repolarization, which affects the QT interval. A variety of changes in ionic current can result in the common effect of decreased repolarizing current, reflected in a long QT, and these changes can secondarily lead to subsequent depolarizing currents and sometimes action potentials, termed afterdepolarizations. This leads to a further delay in repolarization and causes early afterdepolarization (EAD), the triggering event for torsade. The following phases are described:

  • Phase 1: During initial upstroke of action potential in a normal cardiac cell, a rapid net influx of positive ions (Na+ and Ca++) occurs, which results in the depolarization of the cell membrane. This is followed by a rapid transient outward potassium current (Ito), while the influx rate of positive ions (Na+, Ca++) declines. This represents the initial part of the repolarization, or phase 1.
  • Phase 2 is characterized by the plateau, the distinctive feature of which is the cardiac repolarization. The positive currents flowing inward and outward become almost equal during this stage.
  • Phase 3 of the repolarization is mediated by activation of the delayed rectifier potassium current (IK) moving outward while the inward positive current decays. If a slow inactivation of the Ca++ and Na+ currents occurs, this inward "window" current can cause single or repetitive depolarization during phases 2 and 3 (ie, EADs). These EADs appear as pathologic U waves on a surface ECG, and, when they reach a threshold, they may trigger ventricular tachyarrhythmias.

These changes in repolarization do not occur in all myocardial cells. The deep endocardial region and midmyocardial layer (composed of M cells) of the ventricle are more prone to prolongation of repolarization and EADs because they have a less rapid delayed rectifier potassium current (IKr), while other regions might have short or normal cycles. This heterogeneity of repolarization in the myocardial cells promotes the spread of triggered activity, which is initiated by EADs by a reentrant mechanism and currently is thought to be responsible for the maintenance of torsade.2

Mortality/Morbidity

Torsade is a life-threatening arrhythmia and may present as sudden cardiac death in patients with structurally normal hearts.3

Race

For both sexes, the corrected QT interval is longer in white persons than in black persons, possibly explaining the lower susceptibility to acquired torsade in black persons.

Sex

Females are more prone to the development of torsade than males, potentially because they have longer QT intervals.4

Age

Torsade occurs in patients of a wide age range, from newborn to 86 years. If it occurs at an early age, the cause usually is due to congenital long QT syndrome. In later years, the cause usually is due to acquired long QT syndrome.

Clinical

History

Patients with torsade usually present with recurrent episodes of palpitations, dizziness, and syncope; however, sudden cardiac death can occur with the first episode. Nausea, cold sweats, shortness of breath, and chest pain also may occur but are nonspecific and can be produced by any form of tachyarrhythmia.

  • In a young patient with torsade, a diagnosis of congenital long QT syndrome should be considered, especially if a family history of sudden cardiac death or sudden infant death syndrome is present. In these patients, episodes of torsade are triggered by adrenergic stimulation such as stress, fear, or physical exertion, but other predisposing factors also should be considered. See eMedicine article Long QT Syndrome.
  • Patients with Jervell and Lange-Nielsen syndrome commonly have congenital sensorineural deafness representing an autosomal dominant pattern of inheritance for cardiac abnormalities, whereas deafness usually is autosomal recessive.
  • Another form of familial or congenital long QT syndrome is Romano-Ward syndrome, in which hearing is normal and an autosomal dominant pattern of inheritance is observed.
  • Patients with acquired long QT syndrome usually develop torsade during periods of bradycardia.
  • The most common causes of acquired long QT syndrome are medications and electrolyte disorders (eg, hypokalemia, hypomagnesemia). Drug-associated torsade de pointes is relatively rare, but is becoming increasingly common with its incidence as high as 2-3% with certain drugs.
  • Risk factors for torsade include the following:
    • Congenital long QT syndrome
    • Female gender
    • Acquired long QT syndrome (causes of which include medications and electrolyte disorders such as hypokalemia and hypomagnesemia)
    • Bradycardia
    • Baseline electrocardiographic abnormalities
    • Renal or liver failure

Physical

The physical findings in torsade depend on the rate and duration of tachycardia and the degree of cerebral hypoperfusion.

  • Findings include rapid pulse, low or normal blood pressure, or transient or prolonged loss of consciousness. This could be preceded by bradycardia or premature ventricular contractions (leading palpitations).
  • Pallor and diaphoresis may be noted, especially with a sustained episode.
  • Other physical signs depend on the etiology of torsade.

Causes

Congenital long QT syndromes (adrenergic-dependent)

  • Jervell and Lange-Nielsen syndrome
  • Romano-Ward syndrome

Acquired long QT syndromes

  • Drugs
    • Antiarrhythmic drugs
      • Class 1A - Quinidine, disopyramide, procainamide
      • Class III - Sotalol, amiodarone (rare), ibutilide, dofetilide, almokalant
    • Antibiotics - Erythromycin, clarithromycin, azithromycin, levofloxacin, moxifloxacin, gatifloxacin, trimethoprim-sulfamethoxazole, clindamycin, pentamidine, amantadine, chloroquine,
    • Antifungals - Ketoconazole, itraconazole
    • Antipsychotics - Haloperidol, phenothiazines, thioridazine, trifluoperazine, sertindole, zimeldine, fluoxetine (possible)
    • Tricyclic and tetracyclic antidepressants
    • Antihistamines (histamine1-receptor antagonists) - Terfenadine, astemizole, diphenhydramine, hydroxyzine
    • Cholinergic antagonists - Cisapride, organophosphates (pesticides)
    • Diuretics - Indapamide, hydrochlorothiazide, furosemide
    • Antihypertensives - Bepridil, lidoflazine, prenylamine, ketanserin
    • Lithium
    • Other drugs - Anticonvulsants (phenytoin), oral hypoglycemics, citrate (massive blood transfusions), vasopressin (possible), carbamazepine (possible), cocaine, organophosphorus poisoning
    • Some drugs (eg, amiodarone) routinely prolong QT but are less commonly associated with clinical consequences of long QT.5
    • For additional information, see QTsyndrome.ch.
  • Electrolyte abnormalities - Hypokalemia, hypomagnesemia, hypocalcemia
  • Endocrine disorders - Hypothyroidism, hyperparathyroidism, pheochromocytoma, hyperaldosteronism
  • Cardiac conditions - Myocardial ischemia, myocardial infarction, myocarditis, bradyarrhythmia, complete atrioventricular (AV) block
  • Intracranial disorders - Subarachnoid hemorrhage, thalamic hematoma, cerebrovascular accident, encephalitis, head injury
  • Nutritional disorders - Anorexia nervosa, starvation, liquid protein diets, gastroplasty and ileojejunal bypass, celiac disease

More on Torsade de Pointes

Overview: Torsade de Pointes
Differential Diagnoses & Workup: Torsade de Pointes
Treatment & Medication: Torsade de Pointes
Follow-up: Torsade de Pointes
Multimedia: Torsade de Pointes
References
Further Reading

References

  1. Noda T, Shimizu W, Satomi K, Suyama K, Kurita T, Aihara N. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. Eur Heart J. Dec 2004;25(23):2149-54. [Medline].

  2. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. Jan 1994;23(1):259-77. [Medline].

  3. Nikolic G, Bishop RL, Singh JB. Sudden death recorded during Holter monitoring. Circulation. Jul 1982;66(1):218-25. [Medline].

  4. Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol. Jan 1997;29(1):93-9. [Medline].

  5. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation. Aug 1986;74(2):340-9. [Medline].

  6. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. Feb 1988;77(2):392-7. [Medline].

  7. Kurita T, Ohe T, Shimizu W, et al. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes. Pacing Clin Electrophysiol. Jan 1993;16(1 Pt 1):33-8. [Medline].

  8. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol. Nov 1997;20(11):2810-6. [Medline].

  9. Attwell D, Cohen I, Eisner D, et al. The steady state TTX-sensitive ("window") sodium current in cardiac Purkinje fibres. Pflugers Arch. Mar 16 1979;379(2):137-42. [Medline].

  10. el-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res. Sep 1996;79(3):474-92. [Medline].

  11. Gintant GA, Datyner NB, Cohen IS. Slow inactivation of a tetrodotoxin-sensitive current in canine cardiac Purkinje fibers. Biophys J. Mar 1984;45(3):509-12. [Medline].

  12. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. Sep-Oct 1988;31(2):115-72. [Medline].

  13. Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. Mar 2005;111(3):171-6. [Medline].

  14. Kaplinsky E, Yahini JH, Barzilai J, Neufeld HN. Quinidine syncope; report of a case successfully treated with lidocaine. Chest. Dec 1972;62(6):764-6. [Medline].

  15. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. Nov 1983;2(5):806-17. [Medline].

  16. Locati EH, Maison-Blanche P, Dejode P, et al. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol. Jun 1995;25(7):1564-75. [Medline].

  17. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. Mar 4 2004;350(10):1013-22. [Medline].

  18. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. Oct 15 1996;94(8):1996-2012. [Medline].

  19. Salle P, Rey JL, Bernasconi P, et al. [Torsades de pointe. Apropos of 60 cases]. Ann Cardiol Angeiol (Paris). Jun 1985;34(6):381-8. [Medline].

  20. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. May 1 1995;122(9):701-14. [Medline].

  21. Taylor D. Psychotropic drugs, torsade de pointes and sudden death. Acta Psychiatr Scand. Mar 2005;111(3):169-70. [Medline].

  22. Vitelli LL, Crow RS, Shahar E, et al. Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Cardiol. Feb 15 1998;81(4):453-9. [Medline].

Further Reading

Related guidelines

ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices).

(1) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the Management of Acute Myocardial Infarction). (2) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young.

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).

Keywords

torsade de pointes, quinidine syncope, polymorphic ventricular tachycardia, VT, prolonged QT interval, arrhythmia, TdP, torsade de pointes ventricular tachycardia, TdPVT, ventricular fibrillation, early after depolarization, EAD, afterdepolarization, arrhythmia, torsades de pointes, torsades, torsade, sudden cardiac death, SCD, sudden death, ventricular fibrillation, tachyarrhythmia

Contributor Information and Disclosures

Author

Jatin Dave, MD, MPH, Instructor, Department of Medicine, Department of Internal Medicine, Division of Aging, Harvard Medical School; Staff Physician, Brigham and Women's Hospital
Jatin Dave, MD, MPH is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Geriatrics Society, American Medical Association, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Revat Lakhia, MD, Visiting Staff, Department of Internal Medicine, Brigham and Women's Hospital; Graduate Student in Public Health, Department of Health Science, West Chester University of Pennsylvania
Revat Lakhia, MD is a member of the following medical societies: Medical Council of India
Disclosure: Nothing to disclose.

Medical Editor

Justin D Pearlman, MD, PhD, ME, MA, Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Brian Olshansky, MD, Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine
Brian Olshansky, MD is a member of the following medical societies: American Autonomic Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American College of Sports Medicine, American Federation for Clinical Research, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, and New York Academy of Sciences
Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Reliant Grant/research funds Other; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Jeffrey N Rottman, MD, Professor of Medicine and Pharmacology, Director, Clinical Cardiac Electrophysiology Fellowship Program, Vanderbilt University School of Medicine; Chief, Department of Cardiology, Nashville Veterans Affairs Medical Center
Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association and North American Society of Pacing and Electrophysiology (NASPE)
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.